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Christopher C. Thompson et al. / Surgery for Obesity and Related Diseases 15 (2019) 1348–1354 1349Abstract Background: The AspireAssist is the first Food and Drug Administration–approved endoluminal
device indicated for treatment of class II and III obesity.
Objectives: We earlier reported 1-year results of the PATHWAY study. Here, we report 4-year
outcomes.
Setting: United States–based, 10-center, randomized controlled trial involving 171 participants with
the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control arm
receiving Lifestyle Therapy (2:1 randomization).
Methods: AT participants were permitted to continue in the study for an additional year up to a
maximum of 5 years providing they maintained at least 10% total weight loss (TWL) from base-
line at each year end. For AT participants who continued the study, 5 medical monitoring visits
were provided at weeks 60, 68, 76, 90, and 104 and thereafter once every 13 weeks up to week
260. Exclusion criteria were a history of eating disorder or evidence of eating disorder on a vali-
dated questionnaire. Follow-up weight, quality of life, and co-morbidities were compared with
the baseline levels. In addition, rates of serious adverse event, persistent fistula, withdrawal,
and A-tube replacement were reported. All analyses were performed using a per-protocol
analysis.
Results: Of the 82 AT participants who completed 1 year, 58 continued to this phase of the trial.
Mean baseline body mass index of these 58 patients was 41.6 6 4.5 kg/m2. At the end of first year
(at the beginning of the follow-up study), these 58 patients had a body mass index of 34.1 6 5.4
kg/m2 and had achieved an 18.3 6 8.0% TWL. On a per protocol basis, patients experienced
14.2%, 15.3%, 16.6%, and 18.7% TWL at 1, 2, 3, and 4 years, respectively (P , .01 for all). Forty
of 58 patients (69%) achieved at least 10% TWL at 4 years or at time of study withdrawal. Im-
provements in quality of life scores and select cardiometabolic parameters were also maintained
through 4 years. There were 2 serious adverse events reported in the second through fourth years,
both of which resolved with removal or replacement of the A tube. Two persistent fistulas required
surgical repair, representing approximately 2% of all tube removals. There were no clinically sig-
nificant metabolic or electrolytes disorders observed, nor any evidence for development of any
eating disorders.
Conclusions: The results of this midterm study have shown that AT is a safe, effective, and
durable weight loss alternative for people with class II and III obesity and who are willing
to commit to using the therapy and adhere to adjustments in eating behavior. (Surg Obes Relat
Dis 2019;15:1348–1354.)  2019 Published by Elsevier Inc. on behalf of American Society for
Bariatric Surgery.Keywords: Obesity; Endoscopic bariatric therapy (EBT); Aspiration therapy; Metabolic; DietObesity is a major public health problem in the United
States and throughout most of the world because of its
high prevalence and adverse effects (AEs) on health, quality
of life, and healthcare costs [1]. Conservative therapies (diet
and exercise, cognitive behavior therapy, and pharmaco-
therapy) are minimally invasive but with limited long-term
effectiveness [2–5]. Although bariatric surgery is highly
effective, it suffers from low utilization because of its
relative invasiveness [6].
In recent years, there has been a growing interest in
endoscopic bariatric and metabolic therapies. The U.S.
Food and Drug Administration recently approved the
AspireAssist System (Aspire Bariatrics, King of Prussia,
PA, USA) [7]. This is an endoscopic bariatric and meta-
bolic therapies that is approved for adults, 22 years,
with a body mass index (BMI) of 35 to 55 kg/m2 who
have not been successful with conservative therapies. It
is indicated for long-term use, with continuous moni-
toring and lifestyle therapy.Downloaded for Anonymous User (n/a) at Harvard University
For personal use only. No other uses without permission. The AspireAssist consists of a modified percutaneous
endoscopic gastrostomy tube (A tube), with a fenestrated
15-cm long intragastric portion and an external port to facil-
itate partial drainage of gastric contents. Patients are
instructed to aspirate 20 to 30 minutes after a meal up to 3
meals per day. Sullivan et al. [8] showed that optimal aspi-
rating technique resulted in removal of up to 30% of the to-
tal ingested calories.
In an earlier report, we described the 1-year results of the
U.S. pivotal study (PATHWAY trial), which was a prospec-
tive, randomized, controlled, 10-center study. The study ran-
domized 171 patients in a 2:1 fashion to AspireAssist with
lifestyle intervention (AT group) versus lifestyle interven-
tion alone. At 1 year, the AT group experienced a 12.1% to-
tal weight loss (TWL), whereas the lifestyle intervention
alone group experienced a 3.5% TWL (P , .001) [9].
In this report, we provide longer-term results of the pri-
mary outcomes with post hoc analysis of the AT patients
from the PATHWAY Trial. from ClinicalKey.com by Elsevier on March 31, 2020.
Copyright ©2020. Elsevier Inc. All rights reserved.
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Study design
The PATHWAY trial was a 52-week, randomized,
controlled trial conducted at 10 sites in the United States
from November 13, 2012, to June 17, 2015, under the guide-
lines of the Declaration of Helsinki (ClinicalTrials.gov
NCT01766037). The study protocol was previously
described in detail [9]. In brief, patients in both groups
were provided a 10-session behavioral and diet education
weight loss program and were seen for 13 medical moni-
toring visits during the first year. For AT participants who
continued the study, 5 medical monitoring visits were pro-
vided at weeks 60, 68, 76, 90, and 104 and thereafter once
every 13 weeks up to week 260.
All participants provided written informed consent. The
study was approved by the institutional review board at
each institution. All authors were involved in the prepara-
tion of the manuscript, agreed to submit it for publication,
and assumed responsibility for the accuracy and complete-
ness of data from their respective site. The sponsor, Aspire
Bariatrics, funded this clinical trial and provided support for
statistical analyses.Study participants
Inclusion criteria were ages 21 to 65 years old and a BMI
of 35.0 to 55.0 kg/m2. Exclusion criteria were a history of
eating disorder (binge eating disorder, bulimia nervosa, or
night eating syndrome) or evidence of an eating disorder
evaluated by the Questionnaire on Eating and Weight
Patterns-Revised (QWEP-R) or on an Eating Disorder Ex-
amination (EDE), which provide a self-reported measure
and an interview-based assessment of binge eating, purging,
and disordered attitudes and behaviors related to eating,
body-shape, and weight [10,11]. Of 282 patient screens,
there were 8 (2.8%) screening failures owing to Night-
Eating Disorder and 13 (4.6%) screening failures owing to
bulimia or binge-eating disorder. Details regarding subject
eligibility were provided in our earlier paper [9].Statistical analysis
Continuous variables were reported using mean 6 stan-
dard deviation. Categoric variables were reported using pro-
portion (%). A Student’s t test was used to compare
continuous variables and Pearson’s X2 test was used for
comparison of categoric variables. TWL was calculated us-
ing the following formula: (initial weight before AT –
follow-up weight) / initial weight before AT ! 100%.
Excess weight loss (EWL) was calculated using the
following formula: (initial weight before AT – follow-up
weight) / (initial weight before AT – ideal weight) !
100%. Clinical success was defined as achieving at least
10% TWL. A per protocol analysis was used for allDownloaded for Anonymous User (n/a) at Harvard University 
For personal use only. No other uses without permission. Ccalculations in this follow-up study. A Kaplan Meier Sur-
vival analysis was used to assess median survival time of
an A tube. All statistical analysis was performed using
SAS version 9.4 software (Cary, NC, USA). Statistical sig-
nificance was defined as a 2-sided P value  .05.Results
Of 111 patients randomized into the AT group in the
PATHWAY trial, 29 elected to have the A tube removed
for a variety of reasons (Fig. 1) and 82 had the A tube in
place at 1 year, with a TWL of 14.2%. Of 82 patients, 58 pa-
tients elected to continue in this follow-up study. Of these,
55 (94.8%) had achieved at least 10% TWL at the end of
the first year. Mean baseline age of these 58 patients was
43.7 6 9.7 years and mean baseline BMI was 41.6 6 4.5
kg/m2. At the end of first year (at the beginning of the
follow-up study), these 58 patients had a BMI of 34.1 6
5.4 kg/m2 and had achieved an 18.3 6 8.0% TWL.
Weight loss and device usage
Of 58 patients who enrolled in the follow-up study, 15,
21, and 7 patients elected to have the A tube removed
(i.e., withdrew from the study between years 1 and 2, 2
and 3, and 3 and 4, respectively). There was no loss to
follow-up. As a result, the numbers of patients who had
the A tube in place and reported for follow-up at the end
of years 2, 3, and 4 were 43, 22, and 15, respectively. Of
43 patients who withdrew from the study between years 2
and 4, 25 (58.1%) achieved at least 10% TWL at the time
of withdrawal (Fig. 1). On a per protocol basis, patients
experienced 14.2%, 15.3%, 16.6%, and 18.7% TWL at 1,
2, 3, and 4 years, respectively (P , .01 for all). This corre-
sponded to 37.1%, 40.8%, 44.7%, and 50.8% EWL
(Table 1). Mean (6 standard deviation), %EWL, from base-
line, of AT participants at years 1, 2, 3, and 4 was 37.1 6
27.6 (n/N 5 81/110), 40.8 6 25.3 (n/N 5 42/55), 44.7 6
29.7 (n/N 5 22/55), and 50.8 6 31.9 (n 5 15/55), respec-
tively (Table 1). Clinical success rate for patients partici-
pating in the follow-up study was 40/58 (69%) at 4 years
from A-tube placement. The average number of tube con-
nections, or device uses per day, was approximately 2.2
over the first year and 1.5 over the fourth year.
Quality of life
As shown in our prior paper [9], the total Impact of
Weight on Quality of Life score increased at year 1 by
16.3 6 17.7 points from a 63.8 6 17.9 baseline. The score
increased across all 5 measures (physical function, self-
esteem, sexual life, public distress, and work) at year 1.
The improvement observed at year 1 from baseline in
mean total Impact of Weight on Quality of Life score
trended even greater in years 2 to 4 (eTable 1 in
Supplementary Appendix).from ClinicalKey.com by Elsevier on March 31, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
N = 282
Assessed for eligibility
N= 26 Withdrew before treatment
17 gave no reason, changed mind
6 medical issues:
2 lack of family support
1  unhappy with group assignment
N = 70
Control Group
N = 82
AT Group completed 52 weeks
N = 60
Control Group treated 
N = 137
AT Group
N= 29 Withdrew after starting therapy
10 no reason provided/lost to follow-up
6 did not have time for study
5 personal reasons
3 wanted alternative program
2 did not like group assignment
2 other health issues
1 inappropriate behavior
N= 29 Withdrew in Year 1
12 never engaged in therapy
6 job/ time pressures
5 moved out of state
2 family issues
1 interfered with intimacy
1 poor results
1 abdominal discomfort
N = 31 
Control Groupcompleted 52 weeks
N= 10 Withdrew before treatment
8 unhappy with group assignment
2 gave no reason
2:1 Randomization
N = 111
AT Group treated 
N = 58
AT Group started Year 2
N=24 withdrew Week 52
22 did not achieve 10% TBL at 52-weeks
2 met weight loss goals
N=15 withdrew in Year2
11 maintained >10%
3 AEs 
1 did not maintain 10% TBL
N = 43
AT Group completed Year 2
N=21 withdrew in Year 3
11 maintained > 10% TBL 
8 did not maintain 10% TBL
2 AEs
N = 22
AT Group completed Year 3
N=7 withdrew in Year 4
3 maintained ≥ 10% TBL
3 did not maintain 10% TBL
1 AE
N = 15
AT Group completed Year 4
N = 207 Eligible
N = 75 Excluded
22 did not meet inclusion
53 met exclusion
Fig. 1. PATHWAY trial study disposition through year 4.
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At year 1 compared with baseline, glycated hemoglobin,
blood lipids, blood pressure, plasma alanine aminotrans-
ferase, and plasma aspartate aminotransferase had
improved, and this improvement was maintained through
4 years (eTable 2 in the Supplementary Appendix). In the
subset of patients with abnormal or near-abnormal baseline
levels of these parameters, a greater improvement was
observed (eTable 3 in the Supplementary Appendix).
Medications to treat hypertension, dyslipidemia, and dia-
betes were not fixed throughout the study: the participants’
primary physicians changed such medications as they saw
fit. Nonetheless, there was a reduction in medications andDownloaded for Anonymous User (n/a) at Harvard University
For personal use only. No other uses without permission. the number of participants on medications at year 1 from
baseline, and a trend for further reductions in years 2 to 4
(eTable 4 in the Supplementary Appendix).
Electrolytes and minerals
Data on electrolytes (potassium, sodium, chloride, cal-
cium, and CO2) and other analytes (vitamin D, 25-OH,
iron, total protein, blood urea nitrogen, creatinine, and bili-
rubin) at baseline and for years 1 to 4 are provided in
eTables 5 and 6, respectively, in the Supplementary
Appendix. In general, there is little remarkable about these
data in the tables. The mean values at years 1 to 4 were not
clinically or statistically different than the baseline levels from ClinicalKey.com by Elsevier on March 31, 2020.
Copyright ©2020. Elsevier Inc. All rights reserved.
Table 1
Mean (6 standard deviation), %TWL, %EWL, and absolute weight loss (kg), relative to baseline and at
years 1 to 4, with 95% CIs and the percentage of patients who achieved at least 25% EWL at years 1 to 4
N %TWL %EWL WL, kg % EWL .25%
Year 1 82 14.2 6 9.8
95% CI: 12.1–16.4
37.1 6 27.6
95% CI: 31.0–43.1
16.6 6 11.5
95% CI: 14.1–19.1
68.3%
Year 2 43 15.3 6 8.8
95% CI: 12.6–18.0
40.8 6 25.3
95% CI: 32.9–48.7
17.9 6 10.8
95% CI: 14.5–21.3
72.1%
Year 3 22 16.6 6 10.5
95% CI: 12.0–21.3
44.7 6 29.7
95% CI: 31.5–48.7
19.6 6 13.3
95% CI: 13.7–25.5
63.6%
Year 4 15 18.7 6 11.7
95% CI: 12.2–25.2
50.8 6 31.9
95% CI: 33.1–68.5
22.1 6 15.9
95% CI: 13.3–30.9
73.3%
%TWL 5 percent total weight loss; %EWL 5 percent excess weight loss; CI 5 confidence interval.
Christopher C. Thompson et al. / Surgery for Obesity and Related Diseases 15 (2019) 1348–13541352and almost all assessments over this 4-year period, except
for a small percentage, remained in the normal range. There
were no clinical manifestations of any abnormality.
Eating behaviors
Participants were assessed for potential maladaptive
eating behaviors with the QEWP-R, a self-administered
test, and the EDE, a test administered by a qualified health-
care professional. The QWEP-R was given at screening and
weeks 14, 26, 52, 104, 156, 208, and 260. The EDE was
given at screening and weeks 14, 26, and 52.
One participant in the control arm who showed no evi-
dence of binge-eating behaviors at screening demonstrated
evidence of binge eating at week 28, when evaluated by us-
ing the both the QEWP-R and the EDE, and hence was with-
drawn from the study. One AT participant showed no
evidence of any maladaptive eating behavior at week 52
with either her QWEP-R or EDE assessment, but reported
excessive eating at night at week 60 and was withdrawn
from the study. No AT participant ever showed any
abnormal eating behaviors in any of the EDE or QWEP-R
assessments over the 4-year period of this study.
Withdrawals
Of 58 AT participants who continued in the study after
year 1, 43 participants withdrew before completion of
year 4. Of these, 25 of 43 patients (58%) met their weight
loss goal or had lost .10% of their initial weight. Eighteen
of 43 patients (42%) had insufficient weight loss. Of these
18 patients, common reasons for withdrawal included lack
of time or motivation and recurrent site irritation.
Adverse events
Two serious adverse events (SAE) were reported in years
2 through 4 of the study; both resolved with conservative in-
terventions. In the first SAE, a participant at 14 months who
had lost 45 kgs from baseline developed a secondary fistula
just superior to the A-tube fistula. The A tube was removed
and the secondary fistula closed without additional interven-
tion, by the second postexplant visit. In the second SAE, aDownloaded for Anonymous User (n/a) at Harvard University 
For personal use only. No other uses without permission. Cparticipant developed a hole in the A tube 20 months after
placement. The A tube was replaced.
A total of 57 AEs, including the 2 SAEs discussed in the
previous paragraph, occurred in years 2 through 4
(eTable 7). In aggregate, there were .6 AEs per patient-
year in years 2 through 4, compared with a rate of 1.37
AE per patient-year in the postprocedural period of year
1. The 3 AEs with the greatest frequency were peristomal
irritation (12 events), persistent fistulas (12 events), and
peristomal granulation tissue (8 events). In addition to the
1 persistent fistula reported at 6 months in our prior report,
12 persistent fistulas occurred in years 2 through 4 (4 at 2
years, 5 at w2.5 years, 2 at 3 years, and 1 at 4 years); an
additional persistent fistula was reported at 5 years. All
persistent fistulas ultimately closed with 1 to 3 additional in-
terventions (argon plasma coagulator, cytology brush, clips,
or sutures); 2 of 14 persistent fistulas were closed with a sur-
gical intervention, representing 2% of all removed A tubes
(eTable 8, Supplementary Appendix).Special patient population: participants 55 years at
baseline
We looked at weight loss and safety in participants 55
years old at baseline versus participants ,55. Weight loss
at each time period trended slightly higher in the.55 group
than ,55 group, although the difference is not statistically
significant (eTable 9). AEs were similar between the 2
groups (eTable 10).A-tube replacements
Over the 4 years of this study, a total of 27 A tubes have
required replacement. Reasons for A-tube replacement
include (1) a defect developing within the tube (w50%),
(2) leaks around the tube (w30%), and (3) miscellaneous
(diagnostic endoscopy, buried bumper, etc.; 20%). Accord-
ing to a Kaplan Meier survival analysis, one can expect
50% of the A tubes to be replaced within approximately
3.5 years postgastrostomy.from ClinicalKey.com by Elsevier on March 31, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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The results of this study show that AT can provide signifi-
cant and durable weight loss over 4 years in people with class
II and III obesity.Mean%TWLfor those continuing in the trial
improved from14.2%at 1year to18.7%at 4years.Quality-of-
life scores at year 1 also showed significant improvement from
baseline and trended to greater improvement in each subse-
quent year. In addition, the decrease in daily device usage
from years 1 to 4 for those continuing in the trial suggests
adherence to lifestyle modification and not sole dependence
on the device, even for those requiring longer-term therapy.
The study withdrawal rate reported in this study over a 4-
year period was higher than that reported by Nystrom [12] in
which 91%, 76%, 64%, and 57% of the participants who
started AT completed 1, 2, 3, and 4 years of therapy. One
possible explanation is that most of the sites in the Nystrom
study provided more patient-to-patient support than what
was provided in the PATHWAY study (e.g., group therapy
session and Facebook groups).
At year 1, compared with baseline, improvement was
seen in systolic blood pressure, diastolic blood pressure,
high-density lipoprotein, low-density lipoprotein, triglycer-
ides, glycated hemoglobin, plasma alanine aminotrans-
ferase, and plasma aspartate aminotransferase. These
improvements over baseline were maintained, or trended to-
ward greater improvement, for the 3 subsequent years as
well. In addition, with a subset of baseline values that
were abnormal or near-abnormal, at 1 year even greater
improvement was seen. In addition to the improvement in
these cardiometabolic parameters, there was also a reduc-
tion in hypertensive and dyslipidemia medications. This
study offers no evidence that AT has any effect on cardiome-
tabolic parameters beyond those secondary to weight loss.
AEs recorded in years 2 through 4 were no different than
the postprocedural AEs reported in prior studies reporting
PEG tube complications, except for the secondary fistula
as reported above. The majority of AEs in this study were
effectively treated with conservative therapies (short-term
antibiotics, analgesics, topical ointments), resolved without
any treatment, or in some cases required removal or replace-
ment of the A tube. With few exceptions, the AEs reported
in years 1 to 4 of this study were known complications of
percutaneous endoscopic gastrostomy tubes, as reported in
the literature. Of note, the rate of persistent gastrocutaneous
fistulas rose from approximately 2% in the first 2 years to
roughly 33% for tubes in place for longer than 2 years.
The high rate of persistent fistulas after 2 years suggest
that interventions should be taken prophylactically at the
time of A-tube removal for those removed 24 months or
later postgastrostomy. All persistent fistulas eventually
closed with conservative interventions, apart from 2 that
closed with surgical interventions, representing 2% of all
tube removals. The optimal approach for managing this po-
tential AE warrants further study.Downloaded for Anonymous User (n/a) at Harvard University
For personal use only. No other uses without permission. There have been no deaths or permanent disabilities over
the course of this study. In aggregate, 6 participants in this
study experienced a SAE as follows: 2 in the periprocedural
period, 2 in year 1, and 2 in years 2 to 4. These SAEs
resolved with the following conservative therapies: (1) a
2-night hospital stay in which antibiotics were administered,
(2) 2, 1-night hospitalizations in which analgesics were
administered, (3) 2 A-tube replacements, and (4) 2 A-tube
removals.
In this study, patients with a diagnosis of current or pre-
vious eating disorder were not enrolled. Nevertheless, 1 sub-
ject developed increased eating at night. This did not meet
criteria for an eating disorder, but the device was removed.
The concern expressed by some practitioners is that the abil-
ity to aspirate or remove food may be seen as a compensa-
tory behavior and lead to the development of binging in
patients treated with AT, consistent with bulimia nervosa.
Binge eating disorder by itself has a lifetime prevalence of
.855% to 2.6% and a 12-month prevalence of .44% to
1.6% in the general population and is the most common
eating disorder [13–16]. In a population of patients with
obesity who are seeking weight loss treatment, prevalence
of binge eating disorder may be as high as 16% to 52%
[17]. Therefore, it would be expected for a small percentage
of patients with obesity to develop binge eating over the
course of 4 years. Moreover, the rate at which an abnormal
eating behavior occurred in this population of patients with
obesity treated with AT is likely at or below what would be
expected, suggesting that AT does not increase the risk of
developing an eating disorder.
This therapy has the potential of being significantly less
expensive than traditional bariatric surgery, particularly
when the cost of long-term complications is considered.
AT is a 15-minute endoscopic procedure that is performed
in an outpatient setting and typically under conscious seda-
tion. Furthermore, the complications associated with AT are
relatively few and minor and typically resolve with conser-
vative therapies. As such, it may provide an important op-
tion to risk adverse patients that do not wish to undergo
surgical intervention.
Limitations of this study are the relatively small num-
ber of participants in the fourth year and the absence of
weight loss data after A-tube removal, although some
participants stopped using the device for an extended
period of time before A-tube removal without weight
regain because the adoption of new healthy eating behav-
iors is encouraged.
Conclusion
This randomized controlled study has shown that AT can
achieve durable weight loss and provide significant
improvement in quality of life and in cardiometabolic meta-
bolic factors, particularly for patients with a diagnosis of hy-
pertension, dyslipidemia, or type 2 diabetes. In addition, the from ClinicalKey.com by Elsevier on March 31, 2020.
Copyright ©2020. Elsevier Inc. All rights reserved.
Christopher C. Thompson et al. / Surgery for Obesity and Related Diseases 15 (2019) 1348–13541354results of this study support those of prior studies, in addi-
tion to the track record for percutaneous endoscopic gastro-
stomy tubes, to affirm the safety of the intervention.
Considering this, we conclude that AT is a safe and effective
intervention for people with class II and III obesity who
desire a nonanatomy altering procedure and who are willing
to commit to using the therapy.
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